DeCure's autonomous Respiratory AI scientist is researching a drug-repurposing hypothesis for respiratory system disease — screening already-approved drugs against its 42-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleRespiratory system disease maps to a 42-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for respiratory system disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein kinase C theta (PRKCQ) — PRKCQ is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2-oxidanylidene-3~{h}-imidazo[4,5-b]pyridin-1-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5F9E · 2.0 Å · ligand 2,2-dimethyl-7-(2-oxidanylidene-3~{H}-imidazo[4,5-b]pyridin-1-yl)-1-(phenylmethyl)-3~{H}-quinazolin-4-one (5VS). Experimental structure, not a prediction.
What the evidence adds up to
The 2002 review emphasises that for most respiratory diseases, disease burden arises from complex interactions between multiple environmental exposures and genetic factors, rather than single-gene defects or a single strong environmental risk factor alone. The authors state that understanding these gene-environment interactions could lead to earlier identification of susceptible individuals and more effective prevention, and that identifying modifier genes and pathways might reveal new therapeutic targets. No specific drug, clinical trial, or quantitative outcome data are presented in this abstract.
A 2011 chapter notes that respiratory disease is a major public health problem and that advances in available treatments have prolonged life expectancy for many chronic lung conditions. It also states that as survival increases, patient morbidity and adverse impacts on quality of life increase, intensifying demand on healthcare services. No specific drugs, survival rates, or response rates are given.
A 2024 editorial describes a Special Issue compiling advancements in molecular mechanisms, diagnoses, and treatments of respiratory diseases. It provides no concrete data on any drug, no survival or response numbers, and no trial results. The abstracts taken together contain no evidence of efficacy for any specific drug, no contradictory results, and no quantitative outcomes. What is still missing is any controlled trial data, any patient stratification strategy, and any funding for the translational work needed to move from general mechanistic understanding to tested interventions.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Human Genetics · 2002 · 1 citations
The Role of Gene-Environment Interactions in the Development of Respiratory Disorders
AbstractGene-environment interactions are thought to be critical for several respiratory diseases such as COPD and lung cancer. For some pulmonary diseases, the etiology is well understood as a function of single gene defects; for others, the etiology is mainly determined by exposure to some strong environmental risk factor. But for the overwhelming majority of diseases of the respiratory systems, it is clear that the greatest magnitude of disease burden relates to complex interactions between multiple determinants in one’s environment and one’s genetic blueprint. Understanding the fundamental gene-environmental interactions in the development of respiratory disorders such as asthma should lead to earlier identification of susceptible individuals and more effective approaches for disease prevention. Moreover, identifying the genes and the pathways that serve as genetic modifiers of adaptive responses to the changing environmental stimuli could lead to new insights into respiratory biology and the identification of new therapeutic targets.
Oxford University Press eBooks · 2011 · 0 citations
Chapter 1 End-stage respiratory disease
AbstractRespiratory disease is a major public health problem. Advances in available treatments have prolonged the life expectancy for many chronic lung conditions. As survival increases, so does the burden of patient morbidity and the adverse impact on patients' quality of life. In turn, the demand on healthcare services is intensifying....
Molecular Mechanisms, Diagnoses, and Treatments of Respiratory Diseases
AbstractThe Special Issue “Molecular Mechanisms, Diagnoses, and Treatments of Respiratory Diseases” in the journal Biomedicines compiles critical advancements in the understanding of respiratory diseases, focusing on their molecular mechanisms, diagnostic approaches, and therapeutic strategies [...]
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
